The genomic architecture of the 10q22q23 region is characterised by two low-copy repeats (LCRs3 and 4), and deletions in this region appear to be rare. We report the clinical and molecular characterisation of eight novel deletions and six duplications within the 10q22.3q23.3 region. Five deletions and three duplications occur between LCRs3 and 4, whereas three deletions and three duplications have unique breakpoints. Most of the individuals with the LCR3-4 deletion had developmental delay, mainly affecting speech. In addition, macrocephaly, mild facial dysmorphisms, cerebellar anomalies, cardiac defects and congenital breast aplasia were observed. For congenital breast aplasia, the NRG3 gene, known to be involved in early mammary gland development in mice, is a putative candidate gene. For cardiac defects, BMPR1A and GRID1 are putative candidate genes because of their association with cardiac structure and function. Duplications between LCRs3 and 4 are associated with variable phenotypic penetrance. Probands had speech and/or motor delays and dysmorphisms including a broad forehead, deep-set eyes, upslanting palpebral fissures, a smooth philtrum and a thin upper lip. In conclusion, duplications between LCRs3 and 4 on 10q22.3q23.2 may lead to a distinct facial appearance and delays in speech and motor development. However, the phenotypic spectrum is broad, and duplications have also been found in healthy family members of a proband. Reciprocal deletions lead to speech and language delay, mild facial dysmorphisms and, in some individuals, to cerebellar, breast developmental and cardiac defects.
INTRODUCTION
Patients with submicroscopic aberration syndromes have traditionally been recognised by a specific combination of clinical features. 1 When chromosomal banding techniques became available in the 1970s, the cytogenetic basis of many of these syndromes was revealed. [2] [3] [4] [5] The development of subtelomeric fluorescent in situ hybridisation (FISH), targeting all telomeres in a single assay, led to a shift from the original 'phenotype-first' approach to a 'genotypefirst' approach. In the absence of a recognisable phenotype, individuals were screened by FISH for novel submicroscopic chromosomal abnormalities. On the basis of similar genomic aberrations in various patients the clinical presentation was delineated, by a process designated 'reverse phenotypics' . 6 Using new molecular karyotyping techniques such as subtelomeric MLPA and microarray analysis, reverse phenotypics has proven to be successful, by the constantly increasing list of microdeletion/microduplication syndromes. 7 Some of these have a recognisable phenotype, such as the 17q21.31 microdeletion syndrome. [8] [9] [10] Others, such as deletions of chromosome band 1q21.1, 15q13.3 or 16p13.11, give rise to less consistent phenotypes. [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] These aberrations show incomplete penetrance, as demonstrated by their presence in clinically unaffected relatives. Several of these aberrations are associated with an increased risk of neuropsychiatric disorders, such as schizophrenia and autism. 15, 16, 22 Chromosomal anomalies, with an unpredictable and inconsistent phenotypic outcome, represent a difficult counselling situation for clinicians. Microarray analysis during pregnancy is now offered in several countries, and prenatal detection of these submicroscopic changes is a particularly challenging counselling situation. 23 Therefore, the need for extensive information about phenotypic outcomes of such recurrent aberrations is essential.
Recurrent deletions of 10q22.3q23.2 have been characterised by cognitive and behavioural abnormalities. 24 The 10q22.3q23.2 region is characterised by a complex set of low-copy repeats (LCRs), which can give rise to various genomic changes mediated by non-allelic homologous recombination (NAHR). 25 Balciuniene et al 24 described three probands with interstitial deletions in this region. The breakpoints in two of these mapped within these LCRs (LCR3 and LCR4) and inheritance was reported in one. This deletion segregated with a wide range of cognitive and behavioural phenotypes within a large family. The third proband had a complex non-contiguous rearrangement consisting of two deletions with breakpoints in a unique genomic sequence, with the most proximal breakpoint between LCR3 and LCR4 and a telomeric breakpoint B630 kb distal of LCR4. A considerable overlap of cognitive and behavioural phenotypes was noted among probands and affected family members. The presence of LCRs in this region suggests that this locus has an increased susceptibility to chromosomal rearrangements. 24 In contrast to expectations based on the chromosomal architecture defined by LCR3 and LCR4, only six novel deletions and no duplications comprising this region have been reported. 26 Of these, four were clinically assessed.
In this report, we describe the clinical and molecular characterisation of eight novel deletions and six duplications within the 10q22.3q23.3 region. Five deletions and three duplications occur between LCRs3 and 4, whereas three deletions and three duplications have unique breakpoints.
METHODS

Patients and DNA samples
In this study, 14 individuals with an aberration in 10q22q23 were studied. DNA was isolated according to standard procedures. Except for individual 4, who had a 47,XYY karyotype, all others had normal karyotypes by G-banded chromosome studies. Clinical information was obtained from the respective physicians.
The submicroscopic aberrations were detected by array analysis using different array platforms.
All deletions were fine-mapped using high-resolution, custom-tiled oligonucleotide CGH arrays. These were designed, manufactured, processed and analysed by Roche NimbleGen Systems Inc. (Madison, WI, USA). Except for patient 3, all patients were analysed using arrays (design ID 2794) that contained 385 000 isothermal oligonucleotide probes finely tiled across the human chromosome 10 region from 44 to 92 Mb (human genome reference sequence version hg18). Data analysis included 371 000 'unique' probes providing an average coverage of one probe every 130 nucleotides. A probe was considered 'unique' if it differed by at least five nucleotides from homologous hits retrieved by a Blastn search against the entire human genome. Less stringent criteria for 'uniqueness' were applied for probes in LCR sequences, and probes showing only one nucleotide mismatch to paralogous sequences were included for the analysis. Patient 3 was analysed using a different design array (design ID 5621). The chromosome 10 region from 77 to 92 Mb (human genome reference sequence version hg18) was finely tiled with 68 291 probes, which yielded a mean coverage of one probe per 210 nucleotides. All probes on this array were 'unique' , on the basis of the aforementioned criteria. Each sample was subjected to one hybridisation experiment, except for patient 2 whose DNA was subjected to two independent hybridisation arrays. Test DNA samples were labelled with Cy3 and paired with a reference DNA sample labelled with Cy5. We used a human DNA reference sample (Promega) provided by Roche NimbleGen Systems, which is a pool of genomic DNA from six anonymous males. Probe hybridisation signals were expressed as the log2 ratio of signal intensities of a test sample versus signal intensities of a reference sample. Array data were analysed with the segMNT or DNACopy algorithms. More detailed description of probe design, array construction, DNA labelling, hybridisation and data analysis can be found on the Roche Nimblegen Systems webpage (http://www.nimblegen.com/products/ lit/index.html).
In the case of copy number variations (CNVs) with breakpoints mapping within LCRs, the automated segmentation algorithm performed poorly. The breakpoints assigned by analyses of different averaging windows were inconsistent and fell within large genomic intervals up to 5 Mb in length. Instead, we visualised the data using our previously published colour binning method and compared the data of our patients with those from three previously obtained control samples. 24 For patient 2, log2 ratios from two independent experiments were averaged, and the averaged values were used for colour binning analysis. Breakpoint genomic coordinates provided in the result section represent our best estimate, and are in reference to the hg18 version of the Human Genome assembly (http://genome.ucsc.edu/).
RESULTS
Molecular findings
The breakpoints of the deletions and duplications are shown in Figures 1 and 2 
Clinical data
The clinical findings of the patients are described in detail in Supplementary information. The clinical features of probands 1-5 with an LCR3-4 deletion are summarised in Table 1 and of probands 10-12 with an LCR3-4 duplication in Table 2 . The latter table also includes clinical features of patient 9, who had a largely overlapping duplication with breakpoints located in unique sequences outside LCRs3 and 4. The clinical features of probands 6-8 and of probands 13-14 are displayed in Tables 3 and 4 , respectively. Photographs of six patients (cases 1, 3, 4, 9, 10 and 11), whose parents consented for publication, are shown in Figure 3 .
DISCUSSION
In recent years, many recurrent rearrangements have been added to the increasing list of genomic disorders, 27 including deletions in the 10q22.3q23.2 region. 24 The breakpoints of this deletion are flanked by LCRs. LCR3 flanks the proximal breakpoint and harbours two large (4300 kb) highly homologous (99.8% identity) segmental duplications. They are composed of smaller modules with different orientations that are dispersed elsewhere on chromosome 10 and on other chromosomes. LCR4 flanks the distal breakpoint and contains B170 kb of sequence homologous to LCR3, as well as 4100 kb of sequence homologous to LCRs located near the chromosome 10 centromere. 24 On the basis of this genomic architecture, an increased susceptibility of chromosomal rearrangements between LCRs3 and 4 can be expected in this region. However, since the description of two deletions by Balciuniene et al, 24 only six additional cases have been reported. 26 The additional five new cases with the LCR3-4 deletion in the current study were detected within a cohort of 30 991 individuals with MR and/or multiple congenital anomalies, leading to a frequency of 0.016%. This is a much lower frequency than reported for other genomic disorders, such as Williams syndrome (0.31%), 28 proximal 16p11.2 deletions (0.6%), 29 17q21.31 deletions (0.64%) 9 and 15q13.3 deletions (0.24%). 21 On the basis of genomic architecture, the lower frequency might be explained by the B7 Mb unique sequence between the LCRs in the 10q22.3q23.2 region, which is much larger than the distance between segmental duplications in other LCR-mediated recurrent rearrangements reported thus far. The distance between two LCRs is known to be one of the genomic architectural features that influences the efficiency of NAHR. 30 In fact, on the basis of the 18 new genomic disorders described since 2005, recently reviewed by Mefford and (Figure 4 ). [31] [32] [33] [34] [35] [36] In addition, it has been observed that larger-sized genomic rearrangements, using LCRs positioned farther apart, are regularly associated with larger LCRs. 30 Although the aberration on 10q22.3q23.2 is largest in size, its LCRs are intermediate in size compared with LCRs in other genomic rearrangements. The low frequency of 10q22.3q23.2 deletions among MR/MCA individuals may reflect lack of ascertainment because of the mild phenotype in some individuals with this deletion. Balciuniene et al 24 reported multiple family members having this deletion, which segregated with a wide range of cognitive and behavioural phenotypes, including learning difficulties, speech and language delay, ADHD and autism. Individuals with a similar mild phenotype will often not be tested for submicroscopic aberrations. Similar phenotypic variability has been described for other rearrangements, such as on chromosomes 1q21.1, 15q13.3 and 16p13.11. All aberrations are enriched in affected persons compared with control individuals. [12] [13] [14] [15] [16] [18] [19] [20] [21] A less likely explanation for the low frequency might be that 10q22.3q23.2 deletions in foetuses often lead to miscarriages. Although miscarriages were not reported in our families, the family reported by Balciuniene et al 24 showed spontaneous abortions and a stillbirth.
In addition to the six clinically reported 10q22.3q23.2 cases, we present the clinical features of five novel patients with this deletion. Of these 11 deletions, seven had arisen de novo, two were inherited and for two inheritance remained unknown. Two patients had additional In addition, problems with anger control and also with attention have been described. 37 Cognitive development was impaired in all 11 probands, varying from mild to moderate impairment. All patients had apparent speech and language problems. Three patients also had motor developmental delay, but their speech was more severely affected than their motor development.
Patients were mildly dysmorphic, and low-set ears, hypertelorism and a flat nasal bridge were frequently noted. Head circumference ranged from the 3rd centile to above the 97th centile, but the majority of patients were macrocephalic.
Behavioural problems were present in some, but were non-overlapping in type; two patients had autism, 24, 26 two showed hyperactivity 26 and patient 4 demonstrated aggressive behaviour. In the latter, this may have been due to his 47,XYY karyotype. . Proband 1 (a) at 13 years of age; she has upward-slanting palpebral fissures, hypotelorism and low-set ears. Proband 3 (b) at 3 years and 7 months of age; he has dolichocephaly, low-set and prominent ears, hypertelorism, epicanthal folds and a flat midface. Proband 4 (c) at 12 years of age; he has hypertelorism, almond-shaped eyes, low-set ears and full lips. (B) Photographs of patients 9, 10 and 11 with duplications of 10q22.3q23.2. Patient 9 (d) at 9 years of age; he has a triangular face, a broad forehead, upslanting palpebral fissures, slightly deep-set eyes, lateral flaring of eyebrows, prominent ears with thickened horizontal superior helices, a thin upper lip and a smooth philtrum. Sibling patients 10 (e) and 11 (f) show upslanting palpebral fissures, strabismus, hypotelorism, a smooth philtrum and anteverted nares. Two patients had cerebellar anomalies; low-lying cerebellar tonsils in patient 3 and a retrocerebellar cyst with a small cerebellum in patient JHU10qDel-01 were reported by Balciuniene et al. 24 Patient 1 had unilateral congenital breast aplasia. Except for two patients, all other LCR3-LCR4 deletion probands were male. Patients 2 and 4 and case 1 of Alliman et al had a cardiac defect (AVSD, tricuspid and pulmonic regurgitation and persistent ductus arteriosus, respectively) and patient 3 had epilepsy. An AVSD was also noted in patient 7 and epilepsy in patient 8. However, these two latter patients had smaller intragenic deletions, located in unique sequences.
The breakpoints of the deletion in proband 6 were also located in unique sequences, including LCR4 and the PTEN gene. This patient had macrocephaly and juvenile colonic polyps, common features of contiguous gene deletions including tumour suppression genes BMPR1A and PTEN. 38 Germline loss-of-function heterozygous mutations in PTEN have been described, causing an overlapping phenotype including macrocephaly and gastrointestinal polyps in patients with Cowden and Banayan-Riley-Ruvalcaba syndrome. 39 Furthermore, heterozygous germline loss-of-function mutations in BMPR1A cause juvenile polyposis. 40 Three currently reported patients (2, 4 and 7) had a cardiac defect, indicating that a dosage-sensitive gene or genes involved in the pathogenesis of cardiac defects may be located in the 10q22.3q23.2 region. There are two interesting candidate genes located in this region, BMPR1A and GRID1. BMPR1A is deleted in patients 3 and 4 and in all individuals who have been reported with overlapping deletions and cardiac septal defects. [41] [42] [43] [44] [45] Of these deletions, at least one did not include the GRID1 gene. 42 Cardiac-specific deletion of BMPR1A disrupts cardiac morphogenesis in mice, showing ventricular septum, trabeculae, compact myocardium and endocardial cushion defects. 46 BMPR1A was not deleted in patient 7 with a cardiac defect, who had an intragenic deletion of GRID1, which is located only about 500 kb upstream of BMPR1A. The inheritance of this deletion was unknown, hampering conclusions on pathogenicity. Similar deletions have not been reported in the Database of Genomic Variants, nor in the chromosomal databases DECIPHER and ECARUCA. GRID1 encodes for a subunit of glutamate receptor channels, which have a role in mediating excitatory synaptic transmission in the central nervous system. 47 The deletion in patient 7 removes exons 5-8 of the GRID1 gene. The removal of these exons would lead to an in-frame protein that would partly lack the extracellular ligand-binding domain, and therefore may represent a dominant-negative mutation. A recent metaanalysis of genome-wide association data, aimed to identify common genetic variants associated with cardiac structure and function, proposed GRID1 as a candidate gene for left ventricle wall thickness. 48 Remarkably, this glutamatergic gene has also been associated with an entirely different pathology, namely schizophrenia. [49] [50] [51] [52] The glutamatergic system is the major excitatory neurotransmitter system in the central nervous system, 53 and changes in this system are the basis of the 'glutamate hypothesis' aiming to explain symptoms of schizophrenia. 54, 55 After finding linkage evidence for schizophrenia in 10q22 in different populations, [56] [57] [58] [59] GRID1 was implicated as being the causative gene in several association studies. [49] [50] [51] [52] Another gene in the 10q22 region, associated with schizophrenia risk and presentation, is neuregulin 3 (NRG3). 56 This gene is located 2.6 Mb proximal of GRID1 and affected in copy number variation in 12 patients in this study. Neuregulins are signalling proteins that mediate cell-cell interactions in the nervous system, heart, breast and other organ systems. 60 Although several family members of proband 8 had a psychiatric disorder, the intragenic deletion found in the proband and his father did not segregate in the rest of the family. In addition, this intragenic deletion minimally overlaps a CNV (loss) described in two healthy individuals 61 and in our patient 7; however, it extends beyond the CNV telomeric boundary. Therefore, the pathogenic significance of this CNV remains uncertain.
Taking into account that most probands in this study are still young, definitive evidence linking haploinsufficiency of NRG3 or GRID1 to psychiatric disease could not be established.
NRG3 is also a candidate gene for congenital breast aplasia, which was present in patient 1. NRG3 has been implicated in early mammary gland development, and Nrg3 signalling in mice promotes differentiation of mammary epithelial cells at the initial stages of organ formation. Mice harbouring a hypomorphic allele of Nrg3 exhibit defects in mammary gland formation, such as hypoplastic and supernumerary mammary gland formation. 62, 63 NRG3 was also involved in two patients with an intragenic NRG3 duplication and congenital anomalies. Patient 13 had vision problems, most likely because of prematurity, whereas patient 14 had tetralogy of fallot, hypospadias and ambiguous genitalia. Both patients inherited the duplication from an unaffected parent. Although a possible role in organ development cannot be excluded, these duplications did not influence neurocognitive functioning and are most likely non-pathogenic variants.
Three patients (10-12) had a duplication between LCR3 and LCR4. Patient 9 had a duplication that did not involve LCR4, but shared a 5 Mb overlap with the three LCR3-4 duplications. Sibpair patients 10 and 11 inherited this duplication from their healthy mother. The duplication in patient 12 occurred de novo. This patient also had a de novo 16p13.11 deletion, which has been reported as a risk factor, strongly predisposing for, but not sufficient to cause, autism, epilepsy and mental retardation. 13, 20 Duplications involving the 10q22-q23 region are rare. To date, only four cases overlapping this region have been reported. [64] [65] [66] [67] Two of these patients had microcephaly and three had cardiac defects. Precise genotype-phenotype correlations are hampered because these aberrations have often been detected by conventional cytogenetic techniques. In addition, except for one case reported by Dufke et al, 65 these duplications were much larger in size. Patients 9 and 12 displayed speech delay and impaired social interaction. Sibpair patients 10 and 11 were mentally retarded. Probands 9-11 and the patient described by Dufke et al had a strikingly similar facial appearance including a broad forehead, deep-set eyes, upslanting palpebral fissures, a smooth philtrum and a thin upper lip.
As could be noted in the healthy mother of sibpair patients 10 and 11, duplication of the LCR3-4 region does not always lead to an abnormal phenotype. Incomplete penetrance of chromosomal aberrations is a well-known phenomenon, which has been described for several abnormalities such as 1q21.1, 15q13.3, 16p13.11 and 22q11.2 aberrations, [11] [12] [13] [14] 20, 21, [68] [69] [70] [71] with reciprocal duplications of the same interval often less penetrant. 72, 73 To determine the full spectrum and penetrance of the LCR3-4 duplication, more information about probands carrying this duplication, and especially information about other carriers in their families, is needed.
In conclusion, duplications of the LCR3-LCR4 region on 10q22.3q23.2 are associated with variable phenotypic penetrance. In affected individuals, these aberrations may lead to a distinct facial appearance and developmental speech and/or motor function delays. Deletions between LCRs3 and 4 are clinically penetrant in all cases reported thus far. These deletions are associated with cognitive impairment, mainly affecting speech development, and cardiac defects. In addition, these deletions may also be associated with cerebellar and breast developmental defects.
